It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or
consider using other browsers such as Chrome, Firefox or Safari.
Omnitrope (somatropin) injection is a laboratory-created human growth hormone. It is indicated to treat people with:
Formulary coverage of Omnitrope and other somatropins can vary based on indication. The chart below provides indications for somatropins.
GHD=growth hormone deficiency.*Norditropin is also indicated for short stature associated with Noonan syndrome.2
†Nutropin AQ is also indicated for growth failure secondary to chronic kidney disease.3
‡Humatrope and Zomacton are also indicated for SHOX deficiency.4,7
1. Omnitrope [package insert]. Princeton, NJ: Sandoz Inc; 2019.
2. Norditropin [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2020.
3. Nutropin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2016.
4. Humatrope [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2019.
5. Genotropin [prescribing information]. New York, NY: Pfizer Inc; 2019.
6. Saizen [prescribing information]. Rockland, MA: EMD Serono Inc; 2020.
7. Zomacton [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2018.
Omnitrope is given as a subcutaneous (under-the-skin) injection each day or several times a week, as directed by a healthcare professional.
An Omnitrope injection can be administered in two ways:
For more information, please download the Omnitrope Administration Guide
Every patient enrolled in OmniSource has access to a Nurse Trainer to help them learn how to safely administer Omnitrope at home.
The OmniSource Team provides personalized support services to help your patients each step of the way.
Savings support for the journey ahead - eligible patients may pay as little as $0 for their Co-Pay.*
Personalized support, each step of the way. Click here to enroll your patient.
Omnitrope® is a recombinant human growth hormone indicated for:
Please see full Prescribing Information for Omnitrope.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch